Abbvie Inc Common Stock (NYSE: ABBV)


Last Updated: Sep-29-2016 18:47:11

ABBV News & Stock Updates

Click here to read more stories
  • Biotech Boom: (Nasdaq: ABBV), (Nasdaq: PCYC), (NYSE: JNJ)

    Shares of AbbVie Inc. (Nasdaq: ABBV) slipped more than 5% this morning on news that the pharmaceutical giant will purchase Pharmacyclics Inc. (Nasdaq: PCYC) for $21 billion. The deal will give AbbVie access to the very promising blood cancer drug, Imbruvica, although Johnson & Johnson (NYSE: JNJ) currently receives half of the drug's revenue thanks to […]

  • Orphan Profits: (Nasdaq: NPSP), (Nasdaq ADR: SHPG), (Nasdaq: ABBV)

    Shares of NPS Pharmaceuticals Inc. (Nasdaq: NPSP) surged more than 8.5% in pre-market hours on news that the company will be purchased by Ireland's Shire Plc. (Nasdaq ADR: SHPG) for $5.2 billion, or $46 per share. The deal will unite two international firms dedicated to the growing business of developing orphan drugs for rare diseases. This […]

  • What a Deal: (Nasdaq: ESRX), (Nasdaq: ABBV), (Nasdaq:GILD)

    According to reports, Express Scripts Holding Co. (Nasdaq: ESRX) and AbbVie Inc. (Nasdaq: ABBV) have reached an exclusive deal that allows the pharmacy to sell a hepatitis C treatment at a significant discount to customers. According to the deal, Express Scripts will begin discounting the Viekira Pak hepatitis C to the company's 25 million customers on […]

  • The Deal is Done: (Nasdaq: ABBV) and (Nasdaq ADR: SHPG)

    U.S. pharmaceutical company AbbVie Inc. (Nasdaq: ABBV) said it's recommending shareholders abandon the takeover attempt of Dublin-based rival Shire Plc. (Nasdaq ADR: SHPG). The company cited new attempts by the U.S. Treasury Department to curb tax inversions as the primary reason. Shire shares plummeted more than 30% yesterday. Should AbbVie shareholders approve the move, Shire will be paid a break-up fee of roughly […]

  • AbbVie (NYSE: ABBV) Stock Up After Making Biggest Tax Inversion Deal Ever

    AbbVie Inc. (NYSE: ABBV) stock was up 2.45% at noon Friday after the Chicago-based company announced it finally inked a $54.8 billion deal with Ireland-headquartered Shire Plc. (Nasdaq ADR: SHPG) after weeks of back-and-forth negotiations.

    The move has strategic merit in that it gives AbbVie a much-needed new drug portfolio. But it's the substantial tax advantage that figures heavily into the equation.

    Here’s why AbbVie wants Shire – and what the deal means for ABBV stock…
  • Thanks, but No Deal

    British drug manufacturer Shire Plc. (Nasdaq ADR: SHPG) rejected a $46.35 billion bid from rival AbbVie Inc. (Nasdaq: ABBV). The New York Times reported that Shire's board rejected the proposal because the massive bid "fundamentally undervalued the company and its prospects." As M&A activity continues across the sector, investors shouldn't be surprised to see Shire hike its bid up in the coming weeks.

Premium Research

Abbvie Inc Common Stock (NYSE: ABBV) Profile

Volume6,447,501
Open$64.3
Prior Close$64.22
Market Cap$105.53 B
PE Ratio13.83
Beta1.49
AbbVie is a global research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie aims to help patients' live healthier lives and collaborate on sustainable healthcare solutions.
SymbolCompanyMarket cap
JNJJohnson & Johnson$326.17 B
RHHBYRoche Hldg Ltd Spons$214.01 B
PFEPfizer Inc$205.2 B
NVSNovartis Ag$192.59 B
MRKMerck & Company$173.02 B
NVONovo Nordisk A/S$110.82 B
GSKGlaxosmithkline Plc$105.6 B
SNYSanofi-Aventis Sa$98.21 B
BMYBristol-Myers Squibb Company$93.13 B
LLYEli Lilly and Company$89.28 B

ABBV Earnings

1st Quarter Earnings$1.26 (2016-07-29)
2nd Quarter Earnings$1.15 (2016-04-28)
3rd Quarter Earnings$1.13 (2016-01-29)
4th Quarter Earnings$1.13 (2015-10-30)
PE Ratio13.83
EPS Growth12.14%
Recent Earnings$1.26
Annual EPS$4.67
Market Capitalization$105.53 B
Insider Shareholder %0.0011%
Annual Revenue$24.75 B
Number of Shares Outstanding1,679,860 Shares
Institutional Shareholder %68.36%
Annual Net Income$5.72B
TTM Net Profit Margin$23.11
One Year Return22.59%
Three Year Return45.47%
Five Year Return108.65%
Five Year Revenue Growth46.18%
Five Year Earnings Growth61.89%
Five Year Dividend Growth0%
Last Quarter EPS$1.26
Annual EPS$4.67
Annual Dividend$2.28
Annual Dividend Yield3.53%
Change in EPS YTD12.14%
PE Ratio13.83
Recent Earnings$1.26
Dividends per Share$0.57
Stock Split Ratio
beta1.49

ABBV Key Stats

Last Price$62.82
Net Change$-1.4 (-2.18%)
Bid$62.76
Ask Price$63.14
Open Price$64.3
Previous Close Price$64.22
High Price$64.31
Low Price$62.8
Number of Trades24,579
Volume6,447,501
Fifty Two Week High$68.12 (2016-08-15)
Fifty Two Week Low$45.45 (2015-10-22)
Average Daily Volume8,203,548
Share Outstanding1,679,860 Shares
Total Dividend Payout$2.28/yr
Dividend Yield3.53%